Grimes & Company Inc. Trims Stake in Shire PLC (SHPG)
Grimes & Company Inc. cut its stake in Shire PLC (NASDAQ:SHPG) by 46.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,828 shares of the biopharmaceutical company’s stock after selling 15,602 shares during the period. Grimes & Company Inc.’s holdings in Shire were worth $2,766,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in SHPG. SeaCrest Wealth Management LLC bought a new stake in Shire in the fourth quarter valued at approximately $107,000. BB&T Investment Services Inc. boosted its holdings in Shire by 1,672.3% in the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 786 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in Shire in the third quarter valued at approximately $159,000. Benjamin F. Edwards & Company Inc. boosted its holdings in Shire by 277.4% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,253 shares of the biopharmaceutical company’s stock valued at $194,000 after acquiring an additional 921 shares during the last quarter. Finally, New England Research & Management Inc. bought a new stake in Shire in the third quarter valued at approximately $230,000. Institutional investors and hedge funds own 20.31% of the company’s stock.
Shire PLC (NASDAQ SHPG) opened at $133.97 on Wednesday. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire PLC has a 12 month low of $130.57 and a 12 month high of $192.15. The stock has a market capitalization of $42,240.00, a P/E ratio of 25.23, a price-to-earnings-growth ratio of 0.71 and a beta of 1.41.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.